Monoclonal Antibody for the Early Detection of Pancreatic Cancer

Kiron Das (Inventor), Koushik Das (Inventor), Mari Mino-Kenudson (Inventor)

Research output: Innovation

Abstract

Immunoperoxidase staining of mAb Das-1 against low-risk IPMN (left) and high-risk IPMN (right). Gut. 2014 Oct; 63(10):1626-34; 15(11):1009-16 Invention Summary: Pancreatic cancer accounts for 5% of all cancer deaths. Early stages of pancreatic cancer are often asymptomatic. As a result, patients with pancreatic cancer are often diagnosed after the cancer is very advanced, and the 5-year survival rate of the patients is less than 6%. Lots of patients can be saved by early detection and treatment of the precursor lesions of pancreatic cancer, including intraductal papillary mucinous neoplasms (IPMN) and pancreatic intraepithelial neoplasia (PanIN). However, not all patients with IPMN and PanIN develop cancer. Identifying the high risk IPMN and PanIN patients represent an opportunity to treat a pancreatic tumor before it develops into an aggressive, hard-to-treat cancer. A prominent researcher at Rutgers and his collaborators in Harvard Medical School developed a novel monoclonal antibody that reacts strongly and specifically with tissues with high risk IPMN and PanIN. The present invention comprises the use of this antibody as a biomarker to identify the high risk IPMN/PanIN and to determine whether a lesion should be surgically resected. Market Applications: An effective tool to evaluate pancreatic cancer in the more than 4 million Americans with a pancreatic cyst A method for identifying high risk and malignant pancreatic cystic lesions, IPMN, in both tissue and cyst fluid by immunostaining Recent work has demonstrated that this biomarker is superior to all current clinical guidelines and standard cytology Blood-based test is under development This monoclonal antibody has also been shown to be an effective biomarker of preneoplastic changes of esophagus and stomach (separate patents have been issued) Intellectual Property & Development Status: Issued and pending patents; available for licensing and/or collaboration. Reference: Das et al Gut 2014; 63:1626-1634 http://www.ncbi.nlm.nih.gov/pubmed/24277729
Original languageEnglish (US)
StatePublished - Dec 2018
Externally publishedYes

Fingerprint Dive into the research topics of 'Monoclonal Antibody for the Early Detection of Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this